Microbiology – Human food


Crohn's disease biomarkers



Description

In 2014, Scientists from INRA Lab Micalis discovered and validated a panel of bacterial peptide signals associated to CD in a small group of patients in remission or moderate relapse (Juste et al. 2014). These biomarkers were absent or in very low quantity in the digestive system of CD patients in remission or outside an inflammatory period. This discovery is based on quantifications in one particular type of biological matrix (faecal microbiota purified from fresh stool).

Faecal sample patient 1



Particular peptide signals

→ No Crohn's disease

Faecal sample patient 2



Absence of particular peptide signals → Crohn's disease

Type of expected transfer

Licence or licensing option with R&D programme.

Advantages

Highly specific, distinction between UC and CD, non invasive diagnosis from faecal water.

Possible applications

Early diagnosis of CD, distinction between CD and UC, monitoring of CD and treatment.

Key words

Crohn, diagnosis, biomarker, peptide, microbiota



Development level

Patent PCT/FR2015053612 covers nucleotide sequences and coding peptides from intestinal bacteria which are absent in CD patients, as well as the proteomic detection method.

Laboratories: Micalis Lab

Researchers: Catherine Juste

Contact:

Héloïse Simonson, Technology Transfer Officer Email: heloise.simonson@inra.fr Mobile: +33 (0)6 47 05 15 98 Desk: +33 (0)1 42 75 92 51

Date: 14-05-2019

Head Office:28, rue du Dr. Finlay - 75015 Paris - Telephone: +33 1 42 75 95 00 - Fax: +33 1 45 77 6390 A simplified joint-stock company with a capital of 1 920 000€ - RCS PARIS B 433 960 762 - SIRET: 433 960 762 00030 - APE 6630Z - TVA FR 96 433 960 762

INRA Transfer Technology offers : www.inra-transfert.fr